Search for other papers by John E M Midgley in
Google Scholar
PubMed
Search for other papers by Rolf Larisch in
Google Scholar
PubMed
North Lakes Clinical, Department of Nuclear Medicine, Medical Department I, Ruhr Center for Rare Diseases (CeSER), 20 Wheatley Avenue, Ilkley LS29 8PT, UK
Search for other papers by Johannes W Dietrich in
Google Scholar
PubMed
Search for other papers by Rudolf Hoermann in
Google Scholar
PubMed
hypothyroidism that require thyroid hormone replacement (2, 3) . This is mainly done by administration of synthetic levothyroxine ( l -T 4 ), which is a well-established, convenient, safe and inexpensive treatment modality (4, 5) . However, this does not
Diabetes and Endocrine Unit, National Hospital, Kandy, Sri Lanka
Search for other papers by G Amiyangoda in
Google Scholar
PubMed
Search for other papers by C N Antonypillai in
Google Scholar
PubMed
Search for other papers by S S C Gunatilake in
Google Scholar
PubMed
Search for other papers by T T Weerathunge in
Google Scholar
PubMed
Search for other papers by D Ediriweera in
Google Scholar
PubMed
Search for other papers by S G P D Kosgallana in
Google Scholar
PubMed
Search for other papers by R D P Jayawardana in
Google Scholar
PubMed
Search for other papers by H A N D Thissera in
Google Scholar
PubMed
Search for other papers by W J Emalka in
Google Scholar
PubMed
Search for other papers by H U Daraniyagala in
Google Scholar
PubMed
Introduction Refractory hypothyroidism is characterized by an inadequate response to the standard dose of levothyroxine, resulting in persistent biochemical or clinical hypothyroidism ( 1 ). The recommended average daily dose of levothyroxine
Search for other papers by Sílvia Santos Monteiro in
Google Scholar
PubMed
Search for other papers by Tiago Silva Santos in
Google Scholar
PubMed
Search for other papers by Ana Martins Lopes in
Google Scholar
PubMed
Search for other papers by José Carlos Oliveira in
Google Scholar
PubMed
Search for other papers by Cláudia Freitas in
Google Scholar
PubMed
Search for other papers by André Couto Carvalho in
Google Scholar
PubMed
Introduction Oral levothyroxine (LT4) is the mainstay therapy for hypothyroidism. Absorption of oral LT4 occurs primarily in the small intestine within the first 3 h of ingestion, with an absorption rate of 60–80% ( 1 ). Initial LT4 dosing is
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
with levothyroxine TSH suppressive therapy consists in the administration of levothyroxine (LT4) in order to reduce serum TSH levels below the normal range, maintaining normal levels of serum free T4 (FT4) and free T3 (FT3). Based on TSH levels
Search for other papers by Sahar Hossam El Hini in
Google Scholar
PubMed
Search for other papers by Yehia Zakaria Mahmoud in
Google Scholar
PubMed
Search for other papers by Ahmed Abdelfadel Saedii in
Google Scholar
PubMed
Search for other papers by Sayed Shehata Mahmoud in
Google Scholar
PubMed
Search for other papers by Mohamed Ahmed Amin in
Google Scholar
PubMed
Search for other papers by Shereen Riad Mahmoud in
Google Scholar
PubMed
Search for other papers by Ragaa Abdelshaheed Matta in
Google Scholar
PubMed
) evaluate the role of levothyroxine (LT4) replacement therapy on ANGPTL level after 6 months follow-up of achieved euthyroid state among naïve SCH and naïve OH groups in longitudinal arm; (ii) assess the association of ANGPTL3, 4 and 8 with the morphological
Search for other papers by Isabel M Abreu in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar S. João, Alameda Professor Hernâni Monteiro, Porto, Portugal
Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
Search for other papers by Eva Lau in
Google Scholar
PubMed
Search for other papers by Bernardo de Sousa Pinto in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar S. João, Alameda Professor Hernâni Monteiro, Porto, Portugal
Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
Search for other papers by Davide Carvalho in
Google Scholar
PubMed
hypothyroidism should be treated, including those with a serum TSH value below 10 IU/L ( 14 ). To our knowledge, the data regarding the effect of levothyroxine treatment on lipid levels in selected patients, including apolipoproteins, originated from small
Search for other papers by Qingrong Pan in
Google Scholar
PubMed
Search for other papers by Shuxin Gao in
Google Scholar
PubMed
Search for other papers by Xia Gao in
Google Scholar
PubMed
Search for other papers by Ning Yang in
Google Scholar
PubMed
Search for other papers by Zhi Yao in
Google Scholar
PubMed
Search for other papers by Yanjin Hu in
Google Scholar
PubMed
Search for other papers by Li Miao in
Google Scholar
PubMed
Search for other papers by Zhe Chen in
Google Scholar
PubMed
Search for other papers by Guang Wang in
Google Scholar
PubMed
hypothyroidism and hypothyroidism. Furthermore, we investigated the treatment effects of levothyroxine (L-T4) on serum Hcy level and kidney function in hypothyroidism patients, and the association between the changes of Hcy and kidney function after L-T4
Search for other papers by Qing Zhou in
Google Scholar
PubMed
Search for other papers by Li Yong Zhang in
Google Scholar
PubMed
Search for other papers by Mei Feng Dai in
Google Scholar
PubMed
Search for other papers by Zhen Li in
Google Scholar
PubMed
Search for other papers by Chao Chun Zou in
Google Scholar
PubMed
Search for other papers by Hui Liu in
Google Scholar
PubMed
exhibited elevated serum TSH levels but maintained normal thyroid hormone levels compared to control mouse. To normalize TSH levels, mice with subclinical hypothyroidism were provided with levothyroxine in their drinking water for 2 weeks. Levothyroxine (5
Search for other papers by Kusum Lata in
Google Scholar
PubMed
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Subbiah Sridhar in
Google Scholar
PubMed
Search for other papers by Minakshi Rohilla in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by G R V Prashad in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
) . This study will evaluate the obstetric outcome in pregnant women with recurrent miscarriage and response to levothyroxine ( l -T 4 ) therapy. Research design and methods One hundred pregnant and 25 non-pregnant women between 21 and 35 years of age with
Search for other papers by Ulla Schmidt in
Google Scholar
PubMed
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Search for other papers by Ebbe Winther Jensen in
Google Scholar
PubMed
Search for other papers by Jan Kvetny in
Google Scholar
PubMed
Search for other papers by Anne Jarløv in
Google Scholar
PubMed
Endocrine Unit, Department of Medicine, Endocrine Unit, Faculty of Health Sciences, Department of Medicine O, Herlev University Hospital, Herlev Ringvej, DK-2730 Herlev, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
healthy euthyroid subjects, ∼20% of T 3 is derived from thyroidal secretion and the remaining from local production (2) . By contrast, hypothyroid subjects substituted with levothyroxine ( l -T 4 ) monotherapy demonstrated higher plasma T 4 /T 3 ratio